ARTHUR-D-LITTLE
14.3.2024 10:01:27 CET | Business Wire | Press release
Looking beyond current turbulence, the CEOs of the world’s largest companies are increasingly optimistic about future growth, with 66% highly positive about the global outlook over the next three to five years. This is the headline finding of the second annual Arthur D. Little (ADL) CEO Insights Study, which was launched today. The study found that whatever their strategy or sector, global CEOs are increasing their growth investments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314256340/en/
The second annual Arthur D. Little CEO Insights Study was launched today. (Graphic: Business Wire)
Artificial intelligence (AI) is seen as crucial to growth, with 96% of CEOs having already deployed AI in some form, although, demonstrating the early stages of its adoption, just 13% have a compelling, enterprise-wide AI strategy in place.
Importantly, CEOs understand that to get the best from AI, they need to focus on their people. Fifty-nine percent say they have a strong or very strong need to reskill their workforces to meet changing requirements, up from 13% in 2023. This trend is particularly pressing in sectors such as manufacturing, with a 63% increase in the need to reskill, and financial services (+55%).
Alongside AI and reskilling, the third growth focus for CEOs is environmental, social, and governance (ESG). Over three-quarters (77%) are embedding ESG holistically across their organization, with CEOs believing its impact on growth strategies will increase by 26% over the next three years.
Attitudes and plans do vary between sectors and regions. Seventy-eight percent of Asian CEOs forecast positive growth over the next three to five years, compared to 55% of those in South America, for example. Turning to AI, 69% of financial services CEOs had a company wide strategy or strategic view in place, in contrast to 56% of energy & utility companies.
Francesco Marsella, Managing Partner and Global Leader of the Growth and Transformation Practices at Arthur D. Little, comments: “Given today’s business and geopolitical turmoil, it is extremely heartening to see that the CEOs of the world’s biggest companies are positive for the future. The ADL 2024 CEO Insights Study shows that while they accept that conditions will remain volatile and turbulent, they believe a combination of resilient operating structures, clear strategies, AI innovation, and reskilling their people will enable their businesses to thrive in a sustainable future.”
Ignacio García Alves, Chairman and Chief Executive Officer at Arthur D. Little, comments: “The world faces a range of pressing challenges, intensified by current turbulence. Innovation is central to overcoming these issues. Our 2024 CEO Insights Study shows that CEOs agree and are focusing on bringing together AI and human skills to innovate and move forward to ensure future success for their businesses and society as whole.”
The Arthur D. Little 2024 CEO Insights Study interviewed nearly 300 global CEOs leading companies with a turnover of more than $1 billion. Thirty-nine percent headed businesses with annual revenues of over $10 billion. Study respondents are split between key industries and geographies to give unrivaled insight into the minds of those running the world’s biggest organizations.
The full report, including recommendations from ADL, can be downloaded here: https://tinyurl.com/32czp9y9
For further information, please visit www.adlittle.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314256340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
